Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVM CEL-SCI	$9.52 +3.8%	$5.42	$1.98 ▼ $39.30	$63.11M	0.52	367,351 shs	152,267 shs
DTIL Precision BioSciences	$4.96 +4.6%	$4.65	$3.61 ▼ $11.09	$55.87M	1.52	84,524 shs	65,715 shs
IXHL Incannex Healthcare	$0.59 +28.5%	$0.44	$0.08 ▼ $3.12	$13.47M	7.67	130.47 million shs	411.26 million shs
UNCY Unicycive Therapeutics	$4.20 -1.2%	$4.96	$2.83 ▼ $11.00	$75.06M	1.88	480,332 shs	409,439 shs

7 Stocks to Ride The A.I. Megaboom

We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVM CEL-SCI	+3.82%	+9.43%	+51.35%	+279.28%	-72.04%
DTIL Precision BioSciences	+4.64%	+5.31%	+0.40%	+8.30%	-49.54%
IXHL Incannex Healthcare	+28.52%	+54.70%	-41.78%	+170.10%	-68.72%
UNCY Unicycive Therapeutics	-1.18%	-10.64%	-8.89%	-24.08%	+11.70%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CVM CEL-SCI	1.3618 of 5 stars	0.0	4.0	0.0	2.7	1.7	0.6
DTIL Precision BioSciences	4.1627 of 5 stars	3.5	1.0	4.6	3.5	1.7	0.6
IXHL Incannex Healthcare	0.399 of 5 stars	0.0	2.0	0.0	3.1	0.8	0.0
UNCY Unicycive Therapeutics	2.642 of 5 stars	3.7	2.0	0.0	2.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CVM CEL-SCI	0.00	N/A	N/A	N/A
DTIL Precision BioSciences	3.00	Buy	$47.00	847.58% Upside
IXHL Incannex Healthcare	0.00	N/A	N/A	N/A
UNCY Unicycive Therapeutics	3.33	Buy	$60.00	1,328.57% Upside

Current Analyst Ratings Breakdown

Latest IXHL, UNCY, DTIL, and CVM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/27/2025	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$90.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CVM CEL-SCI	N/A	N/A	N/A	N/A	$0.15 per share	N/A
DTIL Precision BioSciences	$1.26M	46.36	N/A	N/A	$2.89 per share	1.72
IXHL Incannex Healthcare	$10K	1,730.48	N/A	N/A	$0.18 per share	3.27
UNCY Unicycive Therapeutics	$680K	109.08	N/A	N/A	$0.93 per share	4.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CVM CEL-SCI	-$26.92M	-$9.77	N/A	N/A	N/A	N/A	-238.05%	-104.65%	N/A
DTIL Precision BioSciences	$7.17M	-$8.81	N/A	N/A	N/A	-6,205.79%	-176.47%	-69.05%	11/3/2025 (Estimated)
IXHL Incannex Healthcare	-$18.46M	-$1.21	N/A	∞	N/A	N/A	-342.92%	-148.64%	9/29/2025 (Estimated)
UNCY Unicycive Therapeutics	-$36.73M	-$4.12	N/A	N/A	N/A	N/A	-243.13%	-119.46%	N/A

Latest IXHL, UNCY, DTIL, and CVM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	UNCY Unicycive Therapeutics	-$0.70	-$0.52	+$0.18	-$0.52	N/A	N/A
8/7/2025	Q2 2025	DTIL Precision BioSciences	-$0.09	-$2.13	-$2.04	-$2.13	$6.27 million	$0.02 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CVM CEL-SCI	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
IXHL Incannex Healthcare	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CVM CEL-SCI	0.66	1.07	1.09
DTIL Precision BioSciences	0.66	5.18	5.18
IXHL Incannex Healthcare	N/A	2.12	2.12
UNCY Unicycive Therapeutics	N/A	2.18	1.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CVM CEL-SCI	12.08%
DTIL Precision BioSciences	37.99%
IXHL Incannex Healthcare	0.43%
UNCY Unicycive Therapeutics	40.42%

Insider Ownership

Company	Insider Ownership
CVM CEL-SCI	9.93%
DTIL Precision BioSciences	4.50%
IXHL Incannex Healthcare	15.49%
UNCY Unicycive Therapeutics	10.71%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CVM CEL-SCI	43	6.88 million	64.67 million	Optionable
DTIL Precision BioSciences	200	11.79 million	11.26 million	No Data
IXHL Incannex Healthcare	3	29.43 million	24.88 million	Not Optionable
UNCY Unicycive Therapeutics	9	17.66 million	11.29 million	Not Optionable

IXHL, UNCY, DTIL, and CVM Headlines

Recent News About These Companies

Wall Street Zen Downgrades Unicycive Therapeutics (NASDAQ:UNCY) to Sell

2 hours ago | americanbankingnews.com

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 14, 2025 in Unicycive Therapeutics, Inc. Lawsuit – UNCY

August 22 at 4:40 PM | globenewswire.com

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics

August 22 at 10:45 AM | globenewswire.com

Kaplan Fox Alerts Investors of Unicycive Therapeutics, Inc. (UNCY) to a Securities Class Action Deadline on October 14, 2025

August 22 at 10:25 AM | theglobeandmail.com

Pomerantz Law Firm Announces the Filing of a Class Action Against Unicycive Therapeutics, Inc. and Certain Officers - UNCY

August 22 at 10:00 AM | prnewswire.com

Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before October 14, 2025 to Discuss Your Rights - UNCY

August 22 at 8:45 AM | prnewswire.com

Class Action Filed Against Unicycive Therapeutics, Inc. (UNCY) - October 14, 2025 Deadline to Join – Contact The Gross Law Firm

August 21 at 3:38 PM | globenewswire.com

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics

August 21 at 11:05 AM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

August 21 at 10:16 AM | globenewswire.com

Shareholders that lost money on Unicycive Therapeutics, Inc.(UNCY) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

August 21 at 8:45 AM | prnewswire.com

Shareholders who lost money in shares of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Should Contact Wolf Haldenstein Immediately.

August 21 at 7:05 AM | prnewswire.com

Shareholders who lost money in shares of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Should Contact Wolf Haldenstein Immediately

August 20 at 4:03 PM | globenewswire.com

UNCY INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Unicycive Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

August 20 at 4:00 PM | prnewswire.com

Unicycive Therapeutics granted new U.S. patent for UNI-494 to treat CKD

August 19, 2025 | msn.com

Unicycive Therapeutics, Inc.: Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease

August 19, 2025 | finanznachrichten.de

Unicycive Posts 65% EPS Gain in Q2

August 19, 2025 | theglobeandmail.com

UNCY INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Unicycive Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

August 18, 2025 | globenewswire.com

UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. ...

August 18, 2025 | gurufocus.com

UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

August 18, 2025 | businesswire.com

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics

August 18, 2025 | businesswire.com

Unicycive Therapeutics (NASDAQ:UNCY) Posts Quarterly Earnings Results, Beats Expectations By $0.18 EPS

August 16, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IXHL, UNCY, DTIL, and CVM Company Descriptions

CEL-SCI NYSE:CVM

$9.52 +0.35 (+3.82%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$9.71 +0.19 (+2.00%)

As of 08/22/2025 08:00 PM Eastern

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Precision BioSciences NASDAQ:DTIL

$4.96 +0.22 (+4.64%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$4.94 -0.01 (-0.30%)

As of 08/22/2025 06:31 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Incannex Healthcare NASDAQ:IXHL

$0.59 +0.13 (+28.52%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.56 -0.03 (-4.25%)

As of 08/22/2025 08:00 PM Eastern

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

Unicycive Therapeutics NASDAQ:UNCY

$4.20 -0.05 (-1.18%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$4.23 +0.03 (+0.62%)

As of 08/22/2025 07:54 PM Eastern

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time